Peer-reviewed veterinary case report
T-cell therapy after chemo helps dogs with non-Hodgkin lymphoma
By O'Connor, Colleen M et al.·Published in Scientific reports·2012·The University of Texas MD Anderson Cancer Center, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.
- Species:
- dog
Plain-English summary
A 7-year-old mixed-breed dog diagnosed with B-lineage non-Hodgkin lymphoma underwent chemotherapy followed by a special treatment called adoptive T-cell therapy. After receiving the chemotherapy, the dog was infused with its own T cells, which had been specially prepared to help fight the cancer. This combination of treatments significantly improved the dog's chances of staying cancer-free for a longer time. The dog showed positive responses, and the T cells were able to target the tumor effectively, leading to better survival outcomes.
People also search for: dog non-Hodgkin lymphoma treatment · adoptive T-cell therapy for dogs · dog cancer survival rates
Abstract
Clinical observations reveal that an augmented pace of T-cell recovery after chemotherapy correlates with improved tumor-free survival, suggesting the add-back of T cells after chemotherapy may improve outcomes. To evaluate adoptive immunotherapy treatment for B-lineage non-Hodgkin lymphoma (NHL), we expanded T cells from client-owned canines diagnosed with NHL on artificial antigen presenting cells (aAPC) in the presence of human interleukin (IL)-2 and IL-21. Graded doses of autologous T cells were infused after CHOP chemotherapy and persisted for 49 days, homed to tumor, and significantly improved survival. Serum thymidine kinase changes predicted T-cell engraftment, while anti-tumor effects correlated with neutrophil-to-lymphocyte ratios and granzyme B expression in manufactured T cells. Therefore, chemotherapy can be used to modulate infused T-cell responses to enhance anti-tumor effects. The companion canine model has translational implications for human immunotherapy which can be readily exploited since clinical-grade canine and human T cells are propagated using identical approaches.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22355761/